Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune

Published 12/12/2023, 14:00
Updated 12/12/2023, 15:10
© Reuters. Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune
PFE
-
BMY
-
SGEN
-
IMGN
-
ABBV
-

Benzinga - by Vandana Singh, Benzinga Editor.

SystImmune and Bristol Myers Squibb & Co (NYSE: BMY) announced an exclusive license and collaboration agreement for SystImmune's BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).

BL-B01D1 has the potential to treat patients with lung and breast cancer, with opportunities to expand into additional tumor types.

SystImmune will be solely responsible for development, commercialization, and manufacturing in Mainland China and for manufacturing certain drug supplies outside of Mainland China.

Bristol Myers Squibb will assume sole responsibility for development and commercialization in the rest of the world.

Bristol Myers will pay SystImmune up to $8.4 billion for the rights, including an $800 million upfront payment to SystImmune and as much as $500 million in contingent near-term payments and additional payments of up to $7.1 billion contingent payments.

William Blair writes that Bristol's (Market Perform rating) decision to in-license another ADC further diversifies and strengthens the company's oncology portfolio amid increasing interest in ADCs among pharma companies.

This ADC investment comes after Bristol Myers' recent acquisition of Orum Therapeutic's ORM-6151 program (anti-CD33 antibody-enabled GSPT1 degrader) in November, as well as a payment of $22.8 million to Tubulis for access to the company's ADC creation platform, and a previous license for MORab-202 from Eisai, William Blair notes.

Last month, AbbVie Inc (NYSE: ABBV) agreed to acquire ADC-maker ImmunoGen Inc (NASDAQ: IMGN) for $10.1 billion, while Pfizer Inc's (NYSE: PFE) $43 billion purchase of Seagen Inc (NASDAQ: SGEN) received all required regulatory approvals just today. Pfizer expects to close the acquisition on December 14.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Price Action: BMY shares are down 0.18% at $51.00 during the premarket session on the last check Tuesday.

Photo Via Company

Latest Ratings for BMY

Mar 2022Wells FargoMaintainsEqual-Weight
Dec 2021Goldman SachsInitiates Coverage OnBuy
Dec 2021Wells FargoInitiates Coverage OnEqual-Weight

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.